Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced HER2+Breast Cancer × Alpelisib × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Neoplasm Metastasis 3 Recurrence 2 Ovarian Neoplasms 2 Lymphatic Abnormalities 2 Lymphangioma, Cystic 2 Lymphangioma 2 Hereditary Sensory and Autonomic Neuropathies 2 Vascular Malformations 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Diseases, Vascular 1 Hyperglycemia 1 Hormone Receptor Positive Breast Carcinoma 1 Head and Neck Squamous Cell Cancer 1 Head and Neck Neoplasms 1 HER2-positive Metastatic Breast Cancer 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Arteriovenous Malformations 1 Advanced HER2+Breast Cancer 1 Advanced Breast Cancer 1

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡